Učitavanje...
Burosumab: A new drug to treat hypophosphatemic rickets
Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on buro...
Spremljeno u:
| Izdano u: | Sudan J Paediatr |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Discover Publishing Group
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845463/ https://ncbi.nlm.nih.gov/pubmed/29545670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.24911/SJP.2017.2.11 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|